Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateHeureSourceTitreSymboleSociété
11/06/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
05/06/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
28/05/202423h20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
25/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
14/05/202422h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
09/05/202414h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
09/05/202414h01GlobeNewswire Inc.ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesNASDAQ:SLRNACELYRIN Inc
09/05/202414h00GlobeNewswire Inc.ACELYRIN, INC. Announces Leadership TransitionNASDAQ:SLRNACELYRIN Inc
29/04/202422h05GlobeNewswire Inc.ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024NASDAQ:SLRNACELYRIN Inc
28/03/202421h05GlobeNewswire Inc.ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
27/03/202421h01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:SLRNACELYRIN Inc
20/03/202412h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
11/03/202413h02GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisNASDAQ:SLRNACELYRIN Inc
11/03/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsNASDAQ:SLRNACELYRIN Inc
15/02/202422h05GlobeNewswire Inc.ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsNASDAQ:SLRNACELYRIN Inc
12/01/202411h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
20/12/202322h30GlobeNewswire Inc.ACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsNASDAQ:SLRNACELYRIN Inc
12/12/202314h00PR Newswire (US)DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Acelyrin, Inc. (NASDAQ: SLRN) and Lead Plaintiff DeadlineNASDAQ:SLRNACELYRIN Inc
28/11/202312h03IH Market NewsTuesday’s Wall Street Highlights: Zscaler, Shein, 3M, Meta Platforms, and MoreNASDAQ:SLRNACELYRIN Inc
27/11/202322h30GlobeNewswire Inc.ACELYRIN, INC. Provides Update on Izokibep Clinical Development ProgramNASDAQ:SLRNACELYRIN Inc
07/11/202322h05GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
06/11/202313h00GlobeNewswire Inc.ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations OfficerNASDAQ:SLRNACELYRIN Inc
31/10/202321h30GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023NASDAQ:SLRNACELYRIN Inc
03/10/202313h00GlobeNewswire Inc.ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of DevelopmentNASDAQ:SLRNACELYRIN Inc
12/09/202315h23IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:SLRNACELYRIN Inc
12/09/202313h29IH Market NewsTuesday’s Wall Street Highlights: Apple, Acelyrin, WestRock, Oracle, UPS, and moreNASDAQ:SLRNACELYRIN Inc
12/09/202302h03Dow Jones NewsStocks to Watch: Oracle, Acelyrin, HumacyteNASDAQ:SLRNACELYRIN Inc
11/09/202322h05GlobeNewswire Inc.ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis SuppurativaNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN